382 related articles for article (PubMed ID: 22292451)
1. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
2. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
3. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
4. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
5. GPR119 agonists 2009-2011.
Buzard DJ; Lehmann J; Han S; Jones RM
Pharm Pat Anal; 2012 Jul; 1(3):285-99. PubMed ID: 24236842
[TBL] [Abstract][Full Text] [Related]
6. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
7. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
[TBL] [Abstract][Full Text] [Related]
8. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
Li H; Fang Y; Guo S; Yang Z
Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
[No Abstract] [Full Text] [Related]
9. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
Expert Opin Investig Drugs; 2013 Apr; 22(4):487-98. PubMed ID: 23442069
[TBL] [Abstract][Full Text] [Related]
10. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
Kang SU
Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
[TBL] [Abstract][Full Text] [Related]
11. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
12. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of type 2 diabetes mellitus.
Israili ZH
Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
[TBL] [Abstract][Full Text] [Related]
14. GPR119 as a fat sensor.
Hansen HS; Rosenkilde MM; Holst JJ; Schwartz TW
Trends Pharmacol Sci; 2012 Jul; 33(7):374-81. PubMed ID: 22560300
[TBL] [Abstract][Full Text] [Related]
15. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
16. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
Dhayal S; Morgan NG
Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
[TBL] [Abstract][Full Text] [Related]
18. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.
Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J
Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion.
Yoshida S; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735
[TBL] [Abstract][Full Text] [Related]
20. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]